Journal of Clinical Endocrinology & Metabolism, Vol 73, 832-836, Copyright © 1991 by Endocrine Society

ARTICLES

Ras oncogene mutations in benign and malignant thyroid neoplasms

H Karga, JK Lee, AL Vickery Jr, A Thor, RD Gaz and JL Jameson
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston 02114.

Current models for tumorigenesis propose that a series of genetic alterations occur during the progression from the normal cell to the malignant phenotype. Mutations in each of the three ras genes (K-ras, H- ras, and N-ras) have been identified in many human neoplasms, including thyroid cancer. In this study we examined genomic DNA from benign and malignant thyroid neoplasms for mutations that are known to activate the ras oncogenes (codons 12, 13, and 61). DNA from frozen surgically excised tissue (n = 8) and from formalin-fixed paraffin-embedded tissue (n = 30) was amplified by the polymerase chain reaction and screened for mutations using oligonucleotide-specific hybridization. No mutations were identified in follicular adenomas (n = 9). In follicular carcinomas, 2 of 14 tumors contained mutations (N-ras 61, Gln to Arg), and both of these patients had bone metastases. One of 15 papillary carcinomas had a ras mutation (H-ras 12, Gly to Ser). In contrast to other studies, we found that ras mutations are relatively uncommon in both benign and malignant thyroid neoplasms. Studies of larger numbers of tumors and comparisons of different patient populations will be required to assess a possible association of mutations in N-ras 61 with clinically aggressive follicular cancer.

This article has been cited by other articles:

				M. Bifulco, A. M. Malfitano, S. Pisanti, and C. Laezza Endocannabinoids in endocrine and related tumours Endocr. Relat. Cancer, June 1, 2008; 15(2): 391 - 408. [Abstract] [Full Text] [PDF]

				A. J. Fikaris, A. E. Lewis, A. Abulaiti, O. M. Tsygankova, and J. L. Meinkoth Ras Triggers Ataxia-telangiectasia-mutated and Rad-3-related Activation and Apoptosis through Sustained Mitogenic Signaling J. Biol. Chem., November 17, 2006; 281(46): 34759 - 34767. [Abstract] [Full Text] [PDF]

				J. A. Knauf, B. Ouyang, E. S. Knudsen, K. Fukasawa, G. Babcock, and J. A. Fagin Oncogenic RAS Induces Accelerated Transition through G2/M and Promotes Defects in the G2 DNA Damage and Mitotic Spindle Checkpoints J. Biol. Chem., February 17, 2006; 281(7): 3800 - 3809. [Abstract] [Full Text] [PDF]

				H. Namba, M. Nakashima, T. Hayashi, N. Hayashida, S. Maeda, T. I. Rogounovitch, A. Ohtsuru, V. A. Saenko, T. Kanematsu, and S. Yamashita Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4393 - 4397. [Abstract] [Full Text] [PDF]

				T. Takano, A. Miyauchi, H. Yoshida, Y. Nakata, K. Kuma, and N. Amino Expression of TR{beta}1 mRNAs with Functionally Impaired Mutations Is Rare in Thyroid Papillary Carcinoma J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3447 - 3449. [Abstract] [Full Text] [PDF]

				V. Vasko, M. Ferrand, J. Di Cristofaro, P. Carayon, J. F. Henry, and C. de Micco Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2745 - 2752. [Abstract] [Full Text] [PDF]

				M. Braga-Basaria and M. D. Ringel Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960. [Abstract] [Full Text] [PDF]

				J. A. Fagin Minireview: Branded from the Start--Distinct Oncogenic Initiating Events May Determine Tumor Fate in the Thyroid Mol. Endocrinol., May 1, 2002; 16(5): 903 - 911. [Abstract] [Full Text] [PDF]

				E. J. Lee, T. J. Kotlar, I. Ciric, M. K. Lee, S. K. Lim, H. C. Lee, K. B. Huh, K. E. Mayo, and J. L. Jameson Absence of Constitutively Activating Mutations in the GHRH Receptor in GH-Producing Pituitary Tumors J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3989 - 3995. [Abstract] [Full Text] [PDF]

				C. D. Malchoff, M. Sarfarazi, B. Tendler, F. Forouhar, G. Whalen, V. Joshi, A. Arnold, and D. M. Malchoff Papillary Thyroid Carcinoma Associated with Papillary Renal Neoplasia: Genetic Linkage Analysis of a Distinct Heritable Tumor Syndrome J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1758 - 1764. [Abstract] [Full Text]

				C. Missero, M. T. Pirro, and R. Di Lauro Multiple Ras Downstream Pathways Mediate Functional Repression of the Homeobox Gene Product TTF-1 Mol. Cell. Biol., April 15, 2000; 20(8): 2783 - 2793. [Abstract] [Full Text]

				A. G. McNees, M. O'Donnell, P. H. Horton, H. Y. Kim, S. J. Kim, C. M. Harris, T. M. Harris, and R. S. Lloyd Lack of Correlation between in Vitro and in Vivo Replication of Precisely Defined Benz[a]anthracene Adducted DNAs J. Biol. Chem., December 26, 1997; 272(52): 33211 - 33219. [Abstract] [Full Text] [PDF]

				T. J. Kotlar, R. H. Young, C. Albanese, W. F. Crowley Jr., R. E. Scully, and J. L. Jameson A Mutation in the Follicle-Stimulating Hormone Receptor Occurs Frequently in Human Ovarian Sex Cord Tumors J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1020 - 1026. [Abstract] [Full Text] [PDF]

				P. Kopp, J. van Sande, J. Parma, L. Duprez, H. Gerber, E. Joss, J. L. Jameson, J. E. Dumont, and G. Vassart Congenital Hyperthyroidism Caused by a Mutation in the Thyrotropin-Receptor Gene N. Engl. J. Med., January 19, 1995; 332(3): 150 - 154. [Full Text] [PDF]